Clinical Trials Directory

Trials / Completed

CompletedNCT02082379

In-Vivo Evaluation of Nebulized Aerosols Delivered Via Nasal Route

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
21 (actual)
Sponsor
Arkansas Children's Hospital Research Institute · Academic / Other
Sex
All
Age
1 Week – 8 Months
Healthy volunteers
Accepted

Summary

We hypothesize that infant and children will show different levels of acceptance of different interfaces while they receive inhaled therapy. We also hypothesize that children will exhibit different amounts of time with the aerosol well aligned with the nostrils during transnasal aerosol delivery.

Detailed description

Aerosol medicine is widely used in treating pulmonary diseases in children. Delivering drugs via aerosol faces several challenges; some are related to the drug and the delivery methods and others to the patient behavior. The latter are crucial and can significantly affect the lung deposition of the drug. Infants are known to be obligate nose breathers making the transnasal route the natural approach for drug delivery in this age group. Different interfaces are already available in the market and are specifically designed to be used in children to improve the child acceptability of the interface and by the result to improve drug deposition. Due to limitations in the use of radiolabeled aerosols and pharmacokinetics/pharmacodynamics studies in infants and children, in-vitro models were developed. These models still lack biological variability which leads to overestimating lung deposition. So, real life correction factors are needed to improve current in-vitro modeling. Previous unpublished data from our laboratory showed that alignment of the aerosol stream with the nostrils is very important for pulmonary deposition. Our objectives are to provide real life data of acceptance of different interfaces by infants and children and to provide a real life correction factor to improve current in-vitro modeling.

Conditions

Interventions

TypeNameDescription
BEHAVIORALinhaled normal saline using different interfaces.A Hudson nebulizer will be loaded with 3 mls of normal saline and operated at 7 L/min of wall air for 3 minutes with each scenario with a 5-minute interval between interfaces. The infants will be videotape while they receive inhaled aerosol, and sound will be captured. The camera will be positioned so the face of the parent holding the child will not be visible.

Timeline

Start date
2014-01-01
Primary completion
2015-02-01
Completion
2015-02-01
First posted
2014-03-10
Last updated
2016-01-07

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT02082379. Inclusion in this directory is not an endorsement.